



Erlonix
Erlotinib 100 mg & 150 mg Tablet

**The oral power to
fight against NSCLC**




The oral power to fight against NSCLC



National Comprehensive Cancer Network (NCCN) Guidelines recommend Erlotinib as an option for **maintenance therapy** based on the SATURN trial

Second/Third-line efficacy and safety

BR. 21 Study design






Erlotinib 100 mg & 150 mg Tablet


The oral power to fight against NSCLC

PFS in the BR.21 intent-to-treat (ITT) population



41%
reduction in risk of cancer progression or death

OS in the BR.21 intent-to-treat (ITT) population



27%
reduction in risk of death

Erlonix

Erlotinib 100 mg & 150 mg Tablet



The oral power to fight against NSCLC



As maintenance therapy

EGFR
MUTATION
POSITIVE

Erlonix
1st-line

EGFR
WILD TYPE
OR UNKNOWN

1st-line
chemotherapy,
then
Erlonix

Dosing and administration

Erlonix
150 mg

once
daily